Trials / Completed
CompletedNCT03509025
Follow-up Study for Participants Jointstem Clinical Trial
Open, Multicenter Follow-up Trial About Active Group of Phase IIb Clinical Trial of JOINTSTEM in Patients With Degenerative Arthritis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 11 (actual)
- Sponsor
- R-Bio · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is a long term follow-up study to investigate the safety of autologous transplantation of Adipose Tissue derived Mesenchymal stem cells (MSCs) in patient with Knee Osteoarthritis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Jointstem | JOINTSTEM is an OA treatment that uses autologous adipose-derived mesenchymal stem cells. As it does not use allogenic tissues and is incubated without additional genetic modification or mechanical and chemical modification through differentiation, it is classified as 'autologous cell therapy' and is completely free of immunologic rejection. |
Timeline
- Start date
- 2017-02-08
- Primary completion
- 2020-12-09
- Completion
- 2020-12-09
- First posted
- 2018-04-26
- Last updated
- 2022-09-28
Locations
2 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT03509025. Inclusion in this directory is not an endorsement.